Navigation Links
Berlin Heart Receives First Regulatory Approval in North America
Date:4/3/2009

BERLIN, April 3 /PRNewswire/ -- Berlin Heart GmbH today announced it has received its first marketing approval in North America. The EXCOR(R) Pediatric ventricular assist device received the License with Conditions from Health Canada, the Federal Department responsible for regulatory issues in Canada.

The Berlin Heart EXCOR Pediatric is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used as a short-term, mid-term, and long-term support system, supporting failing hearts from days up to several months.

The system is designed to bridge patients awaiting heart transplantation until a donor heart becomes available, but has also been used successfully as a bridge to recovery when a patient's heart was able to recover and work on its own again. Unlike other VADs, EXCOR Pediatric can be used to support children of all age groups, from newborns up to teenagers.

Dr. Johannes Muller, General Manager of Berlin Heart, comments: "The license with conditions represents a milestone reached for children and teenagers suffering from severe heart failure, as the system is now more readily available in Canada. Since patients often require acute emergency support, this is a major step toward improved care for these potentially terminally ill children."

Since the application for Canadian regulatory approval in September 2007, 21 patients were supported in Canada with EXCOR Pediatric under special access approval.

About EXCOR(R) Pediatric

EXCOR Pediatric is a pulsatile, pneumatically driven ventricular assist device and can be used to support one or both ventricles. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newborns with 2.2 kg body weight to teenagers. Since the first application of the ventricular assist device in Canada in July 2002, 39 children and teenagers have been supported with EXCOR Pediatric. EXCOR is currently under clinical investigation for pediatric patients in USA.

About Berlin Heart

Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices for patients of every age and body size. The company offers pumps, cannulas, and external components for internal and external use to stabilise cardiac activity in acutely ill patients. The company is market leader in Germany and Europe.

The company also manufactures the implantable left ventricular assist device INCOR(R), which has been designed for long-term application in adult patients. The longest the device has supported a patient so far is more than five and a half years and ongoing. INCOR is not FDA approved, but widely used in Europe.

    Contact:
    Linda Buerk
    Manager Marketing & PR
    Phone: +49(0)30-8187-2650
    Mobile: +49(0)173-629-0803
    buerk@berlinheart.de


'/>"/>
SOURCE Berlin Heart GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
2. Drug for cluster headaches may cause heart problems
3. Use of certain lipid measures not more effective in predicting coronary heart disease
4. Restricting Blood Flow May Help Heart Bypass Patients
5. Urban Smog Tough on Young Adults Hearts
6. Stanford study highlights cost-effective method of lowering heart disease risks
7. Vitamin Es lack of heart benefit linked to dosage
8. Drug That Lowers Resting Heart Rate Being Tested
9. Heart Attack Boosts Diabetes Risk
10. Embryonic Stem Cells Repair Human Heart
11. U of M study: Early treatment can reverse heart damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology: